- Conditions
- Dry Eye Disease
- Interventions
- Reproxalap ophthalmic solution (0.25%), Vehicle ophthalmic solution
- Drug
- Lead sponsor
- Aldeyra Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 421 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Shelby, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 610
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Dry Eye Disease
- Interventions
- SI-614, Placebo
- Drug
- Lead sponsor
- Seikagaku Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 232 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 6
- States / cities
- Newport Beach, California • Louisville, Kentucky • Andover, Massachusetts + 3 more
- Conditions
- Dry Eye Syndromes
- Interventions
- Lubricant Eye Drops (Optive™), Lubricating Eye Drops (blink® Tears)
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Chevy Chase, Maryland
- Conditions
- Keratoconjunctivitis Sicca, Dry Eye Disease
- Interventions
- Lifitegrast, Placebo
- Drug
- Lead sponsor
- Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 588 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 13
- States / cities
- Waterbury, Connecticut • Louisville, Kentucky • Augusta, Maine + 10 more
- Conditions
- Fuchs Endothelial Corneal Dystrophy
- Interventions
- Ripasudil, Placebo
- Drug
- Lead sponsor
- Kowa Research Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 26
- States / cities
- Los Angeles, California • Palo Alto, California • Sacramento, California + 20 more
- Conditions
- Cystinosis
- Interventions
- Cysteamine
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 2 Years and older
- Enrollment
- 328 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1986 – 2013
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Cataract, Glaucoma, Ocular Hypertension
- Interventions
- Bimatoprost Implant System, SpyGlass IOL, Timolol Maleate Ophthalmic Solution, 0.5%, Commercial IOL
- Drug · Device
- Lead sponsor
- SpyGlass Pharma, Inc.
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Posterior Blepharoconjunctivitis
- Interventions
- Azithromycin ophthalmic solution, 1%
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Blepharitis
- Interventions
- Azithromycin ophthalmic solution, 1%, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009
- U.S. locations
- 26
- States / cities
- Scottsdale, Arizona • Fayetteville, Arkansas • Artesia, California + 21 more
- Conditions
- Diabetes
- Interventions
- Human Pancreatic Islet Transplantation
- Biological
- Lead sponsor
- Midhat H. Abdulreda
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 2
- States / cities
- Miami, Florida
- Conditions
- Non-infectious Anterior Uveitis
- Interventions
- TRS01 eye drops
- Drug
- Lead sponsor
- Tarsier Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 2
- States / cities
- Palisades Park, New Jersey • San Antonio, Texas
- Conditions
- Myopia
- Interventions
- Multi-Purpose Disinfecting Solution (OPTI-FREE RepleniSH), Contact Lenses
- Device
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Keratoconus
- Interventions
- GLK-221 Ophthalmic Solution, Placebo Ophthalmic Solution
- Drug
- Lead sponsor
- Glaukos Corporation
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Westerville, Ohio
- Conditions
- Allergic Conjunctivitis
- Interventions
- Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution
- Drug
- Lead sponsor
- Aldeyra Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 318 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Sacramento, California • Torrance, California + 3 more
- Conditions
- Epiphora, Dacryostenosis, Dacryocystitis
- Interventions
- Proparacaine Hydrochloride ophthalmic solution, USP 0.5%, Balanced salt solution
- Drug
- Lead sponsor
- Louisiana State University Health Sciences Center in New Orleans
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Dry Eye
- Interventions
- SYSTANE Ultra, Optive
- Other
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Fort Worth, Texas
- Conditions
- Dry Eye
- Interventions
- Systane Ultra Lubricant Eye Drops, Optive Lubricant Eye Drops
- Other
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Months and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- North Andover, Massachusetts
- Conditions
- Glaucoma
- Interventions
- BL1107 Low dose, BL1107 High dose, Timolol maleate 0.5%
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 14
- States / cities
- Glendale, California • Newport Beach, California • Pasadena, California + 11 more
- Conditions
- Anesthesia, Local
- Interventions
- AG-920, Proparacaine Ophthalmic
- Drug
- Lead sponsor
- American Genomics, LLC
- Industry
- Eligibility
- Up to 10 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- McAllen, Texas
- Conditions
- Ocular Hypertension, Open-angle Glaucoma
- Interventions
- Timolol maleate Ophthalmic Solution 0.5% BID, AR-13324 Ophthalmic Solution 0.02%, Placebo
- Drug · Other
- Lead sponsor
- Aerie Pharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 411 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Bedminster, New Jersey
- Conditions
- Dry Eye Disease
- Interventions
- 0.003% AR-15512 ophthalmic solution, Artificial Tears
- Drug · Other
- Lead sponsor
- Alcon Research
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 4
- States / cities
- Louisville, Kentucky • Garner, North Carolina • Leland, North Carolina + 1 more
- Conditions
- Ocular Hypertension, Open Angle Glaucoma
- Interventions
- Netarsudil ophthalmic solution 0.02%, Netarsudil Ophthalmic Solution Vehicle
- Drug · Other
- Lead sponsor
- Aerie Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016
- U.S. locations
- 1
- States / cities
- Bedminster, New Jersey
- Conditions
- Corneal Edema
- Interventions
- Netarsudil Ophthalmic
- Drug
- Lead sponsor
- Aerie Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 12
- States / cities
- Garden Grove, California • Laguna Hills, California • Edgewood, Kentucky + 9 more
- Conditions
- Ocular Discomfort
- Interventions
- Bausch & Lomb Multi-Purpose Solution, Ciba's Multi-Purpose Solution
- Device
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 312 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Rochester, New York